SQI Diagnostics Enters New Revenue Agreement

SQI Diagnostics (TSXV:SQD; OTCQX:SQIDF) announced a new agreement with a pharmaceutical customer to provide assay development and sample testing services.
As quoted in the press release:

This pharmaceutical customer has a unique need to measure how their drugs interact with a key biomarker in the human body by measuring antibody levels. SQI is in a unique position with its multiplexing technology to develop an automated, multiplexed test to measure these drug-biomarker interactions.
In addition, because of the sensitive timeframe of this project, the customer has also engaged SQI to provide contract research services to provide the analytical sample testing, which could be in excess of 1000 samples for which the customer will be charged a per-sample fee.  This testing will be done at SQI’s state-of-the-art facility in Toronto.
“We are excited to sign this agreement with such a large and respected institution in the pharmaceutical and biotechnology space,” said Andrew Morris, CEO of SQI Diagnostics. “This also presents the largest customer to date that has engaged SQI to provide sample testing services which is a new and burgeoning business for SQI.”

Click here to read the full press release.

Source: www.newswire.ca